Minerva Urology and Nephrology最新文献

{"title":"DCOM: a 3D virtual imaging-based nephrometry scoring system for robot-assisted partial nephrectomy.","authors":"Zhengsheng Liu, Tao Wang, Zongkai Zhang, Wei Li, Xuegang Wang, Kaiyan Zhang, Zhun Wu, Zhipeng Li, Zhongjie Zhao, Chaohao Miao, Yu Luo, Bin Chen, Jinchun Xing","doi":"10.23736/S2724-6051.25.06002-1","DOIUrl":"https://doi.org/10.23736/S2724-6051.25.06002-1","url":null,"abstract":"<p><strong>Background: </strong>The aim of this paper was to establish a new surgical difficulty scoring system of robot-assisted partial nephrectomy (RAPN) based on three-dimensional (3D) virtual imaging.</p><p><strong>Methods: </strong>We collected data from the patients subjected to robot-assisted surgery. 296 presented complete demographic and clinical data including RAPN and robot-assisted radical nephrectomy (RARN). Researchers used preoperative enhanced CT or MRI image data, and 3D image reconstruction, 4 independent variables were assessed: diameter of tumor inside kidney (D); compression of the renal segmental vessels; occupation of the renal sinus; mass exophytic rate (DCOM). DCOM score was then used to aid surgical decision-making and guide surgical strategy planning. The predictive values of DCOM score were analyzed using a multinomial logistic regression mode.</p><p><strong>Results: </strong>We confirmed that DCOM score as predictor of surgical outcome significantly outperformed the other common predictors used (RENAL and PADUA score).</p><p><strong>Conclusions: </strong>The surgical difficulty scoring system (DCOM scoring system) of partial nephrectomy (PN) based on 3D virtual imaging-based nephrometry system could provide a basis for the formulation of preoperative surgical strategy, but further verification is needed.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":"77 3","pages":"308-319"},"PeriodicalIF":4.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sexual function outcomes in men undergoing minimal invasive ablative techniques for prostate cancer: a ESRU/YAU urotech systematic review and pooled analysis.","authors":"Federico Piramide, Alessandro Veccia, Lazaros Tzelves, Sven Nikles, Luis E Ortega Polledo, Luigi Nocera, Adrian Khelif, Leo Dumbovic, Lazaros Lazarou, Edoardo Cisero, Alberto Quarà, Andrea Sterrantino, Ugo Falagario, Pietro Piazza, Loic Baekealndt, Diego M Carrion, Juan Gomez Rivas, Giovanni Cacciamani, Enrico Checcucci","doi":"10.23736/S2724-6051.25.06007-0","DOIUrl":"https://doi.org/10.23736/S2724-6051.25.06007-0","url":null,"abstract":"<p><strong>Introduction: </strong>In the latest years the advent of minimally invasive focal treatment for prostate cancer (PCa) has gained a wide diffusion. Different platforms and sources of energy have been developed (HIFU, cryotherapy, focal brachytherapy…) and reported to be able to effectively treat PCa with minimal impact on sexual function. The aim of this systematic review is to summarize, evaluate and compare the impact of these focal therapies on the sexual function (erectile and ejaculatory function) of men harboring low to intermediate risk PCa.</p><p><strong>Evidence acquistion: </strong>A systematic literature search was conducted in October 2022 and updated in August 2024 using Medline (via PubMed), Embase (via Ovid), Scopus, and Web of Science (registered on PROSPERO as CRD42022370237). The search strategy used PICO criteria and article selection was conducted following the PRISMA guidelines. The risk of bias and the quality of the articles included were assessed. A dedicated data extraction form was used to collect the data of interest.</p><p><strong>Evidence synthesis: </strong>Overall, our electronic search identified 4465 papers, 96 of which ultimately met the inclusion criteria and thus were included in the analysis. Among them, 87 were single arm studies, eight were comparative studies, whilst only 1 was a randomized prospective study. Overall, 6244 patients were evaluated (2318 HIFU, 2034 focal cryoablation, 1194 irreversible electroporation [IRE], 346 focal laser ablation [FLA], 147 high-dose brachytherapy [HDB], 247 Vascular photodynamic therapy [VPT], 21 focal microwave ablation [FMA], 151 low-dose brachytherapy [LDB], 10 focal bipolar radiofrequency ablation [FBRA] and 22 trans-urethral ultrasound ablation [TULSA]). The most reported measure of sexual function was IIEF-5, with baseline scores ranging from 16.2 (IRE) to 22.35 (VPT). At 12 months post-treatment, VPT and high-dose brachytherapy had the highest IIEF-5 scores (20.01 and 19.90, respectively), while cryotherapy, low-dose brachytherapy, and HIFU had the lowest (14.08, 14.94, and 15.40, respectively). Ejaculatory function was underreported, with only two studies assessing its preservation after HIFU. Safety analysis showed an overall complication rate of 21%, with major complications occurring in 1.4% of cases.</p><p><strong>Conclusions: </strong>FT offers a promising balance between oncologic control and functional preservation in low- to intermediate-risk PCa. However, significant variability in FT modalities, ablation strategies (focal vs. hemigland vs. zonal), and outcome assessment methods limits direct comparisons. Future prospective studies with standardized protocols and long-term follow-up are essential to optimize patient selection and improve functional outcomes.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":"77 3","pages":"285-297"},"PeriodicalIF":4.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overactive bladder: results from patients treated by hyaluronic acid-chondroitin sulphate therapy.","authors":"Roberto Falabella, Simone Morra, Luigi Milella, Sabrina LA Falce, Giuseppe DI Fino, Saveriano Lioi, Franco C Ponti, Aldo DI Fazio, Vito Mancini, Felice Crocetto, Vincenzo F Caputo, Giuseppe Carrieri","doi":"10.23736/S2724-6051.24.05786-0","DOIUrl":"10.23736/S2724-6051.24.05786-0","url":null,"abstract":"<p><strong>Background: </strong>Overactive bladder (OAB) is a chronic condition. This study was prompted by the need to fill the gap between medical treatment and advanced therapies allowing improvement in Quality of Life. The aim of the current study was to evaluate the association between treatment type (Ialuril^®; IBSA Farmaceutici, Lodi, Italy; in combination with antimuscarinic or alone after drop-out of antimuscarinic, relative to antimuscarinic alone treatment) and functional outcomes (number of micturitions, pelvic pain, urinary incontinence, nocturia, urgency).</p><p><strong>Methods: </strong>Of all patients newly diagnosed (January 2016 - January 2022) with OAB syndrome, we retrospectively identified 150 patients. They harbored three groups of 50 patients each: group 1 (antimuscarinic drug), group 2 (antimuscarinic drug + hyaluronic acid-chondroitin sulphate [HA-CS]), group 3 (antimuscarinic dropout patients). Univariable linear and logistic regression models were fitted for number and rates of incontinence, urgency, pelvic pain, nocturia, respectively.</p><p><strong>Results: </strong>A significant mean reduction of 1.5 micturition (P=0.02) was recorded in group 2 compared to group 1. Conversely, no statistically significant mean difference was recorded in group 3 compared to group 1. Regarding pelvic pain, both group 2 and group 3 were associated with lower rate of pelvic pain (P<0.001). Regarding urgency, a statistically significant protective OR was recorded for group 2 (OR=0.39; P=0.04), compared to group 1.</p><p><strong>Conclusions: </strong>The combination therapy was associated with symptom improvement in antimuscarinic naïve OAB patients. Conversely in antimuscarinic dropped-out patients only pelvic pain improved with the HS-CA. No statistically significant differences were recorded for other functional outcomes, such as incontinence and nocturia.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":"375-382"},"PeriodicalIF":4.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Partial penectomy with glans reconstruction: technical modification.","authors":"Guglielmo Mantica, Benedetta Col, Federica Balzarini, Giorgia Granelli, Tommaso Saccucci, Carlo Terrone","doi":"10.23736/S2724-6051.25.06466-3","DOIUrl":"10.23736/S2724-6051.25.06466-3","url":null,"abstract":"","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":"441-442"},"PeriodicalIF":4.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144052772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Percutaneous ablation of renal tumors in patients with a solitary kidney: medium- to long-term outcomes.","authors":"María E Perez Montilla, Pedro B García Jurado, Enrique Gómez Gómez, Sara Barranco Acosta, María S Lombardo Galera, Pablo J Campos Hernández, Juan J Espejo Herrero","doi":"10.23736/S2724-6051.25.06010-0","DOIUrl":"https://doi.org/10.23736/S2724-6051.25.06010-0","url":null,"abstract":"<p><strong>Background: </strong>This work aims to evaluate safety, medium- and long-term efficacy, and renal function outcomes of percutaneous ablation (PA) of renal masses in patients with a solitary kidney (PSK).</p><p><strong>Methods: </strong>This retrospective, single-center study enrolled 53 consecutive tumors in 33 PSK from April 2004 to October 2021. Renal tumors were treated with image-guided PA. Clinical data, radiographic characteristics, and complications at 30 days were collected. Follow-up involved clinical and radiological imaging to assess technical efficacy and recurrence. Serum creatine and glomerular filtration rate (GFR) for measuring renal function were determined at baseline, 12 months, and end of follow-up.</p><p><strong>Results: </strong>Thirty-three PSK (21 male) aged 35 to 85 years were treated for 53 renal tumors. The mean size was 25.8 mm (IQR 17.5-30). The mean RENAL and PADUA scores were 6.3 (IQR 4.5-8) and 8 (IQR 6-10). Nine complications (Clavien-Dindo grade I, II, III) occurred in 42 sessions. RENAL and PADUA scores and endophytic localization were significantly associated with complications. Technical efficacy after one session was 88.7%; The mean follow-up time was 45.8 months (IQR 18-48). There were five local recurrences (10%) at a mean of 28 months (IQR 17-40). GFR declined 14.8% at 12 months. GFR declines were 13 mL/min/m² in patients with one lesion and 26.9 mL/min/m² with two or more (P=0.048). Two patients required hemodialysis.</p><p><strong>Conclusions: </strong>PA is a safe treatment option in PSK that provides good long-term cancer control and minimal clinical impact on postoperative renal function.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":"77 3","pages":"347-355"},"PeriodicalIF":4.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of antibiotic treatment duration for preoperative asymptomatic bacteriuria, during urological surgery, on postoperative infectious complications: results from the multicentric TOCUS cohort.","authors":"Humphrey Robin, Stessy Kutchukian, Pierre Bigot, Marc Françot, Stéphane de Vergie, Jérôme Rigaud, Mathilde Chapuis, Laurent Brureau, Camille Jousseaume, Omar Karray, Fares T Kosseifi, Aurélien Descazeaud, Harrison-Junior Asare, Maxime Gaullier, Baptiste Poussot, Thibault Tricard, Shahed Borojeni, Bastien Gondran-Tellier, Michael Baboudjian, Éric Lechevallier, Pierre-Olivier Delpech, Elias Ayoub, Héloïse Ducousso, Simon Bernardeau, Aurélien Dinh, Franck Bruyère, Maxime Vallée","doi":"10.23736/S2724-6051.24.05725-2","DOIUrl":"10.23736/S2724-6051.24.05725-2","url":null,"abstract":"<p><strong>Background: </strong>According to the European guidelines, any urological surgery breaching the mucosa requires preoperative screening and antibiotic treatment of any asymptomatic bacteriuria (ABU).</p><p><strong>Methods: </strong>The aim of this study was to determine whether the preoperative antibiotic treatment duration of ABU in urological surgery impact postoperative infectious complications. National multicenter, retrospective study including all consecutive patients screened for ABU before urologic surgery in 10 centers from 1^st April 2019 to April 2023. The primary endpoint was all postoperative infectious complications occurring within 30 days after surgery. Short antibiotic treatment (SAT) of ABU was defined by 5- day regimen or less. Long antibiotic treatment (LAT) was defined by duration longer than 5 days.</p><p><strong>Results: </strong>Among the 2389 patients included, 839 (35.1%) patients had positive urine culture (UC), of whom 546 (65%) had positive mono or bimicrobial UC and 292 (34.8%) polymicrobial UC. There were 106 (4.4%) postoperative infectious complications occurring within 30 days including 62 (58.5%) in the positive UC group. In the positive UC group, 336 (40%) had received SAT, 261 (31.1%) LAT and 231 (27.5%) had not received any treatment. The 30-day surgery-related infection rates were 8.3%, 6.1% and 7.36% respectively. There was no statistical difference between SAT versus LAT in the univariate analysis (P=0.6) or in the multivariate analysis OR 1.97 [0.37, 1.86] (P=0.06).</p><p><strong>Conclusions: </strong>Our results found no association between antibiotic treatment duration and urinary infectious complication among patients with preoperative ABU who undergo urological surgery. These results need a RCT to be confirmed.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":"365-374"},"PeriodicalIF":4.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: \"From nocturnal awakenings to nocturnal voiding: the relationship between insomnia and nocturia - a systematic review\".","authors":"Beatrice Turchi, Riccardo Lombardo, Antonio Franco, Sabrina DE Cillis, Vincenzo Li Marzi, Ferdinando Fusco, Cosimo DE Nunzio","doi":"10.23736/S2724-6051.25.06522-X","DOIUrl":"https://doi.org/10.23736/S2724-6051.25.06522-X","url":null,"abstract":"","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":"77 3","pages":"432-434"},"PeriodicalIF":4.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility and setting of single docking HUGO RAS robot-assisted nephroureterectomy: first European experience.","authors":"Angelo Mottaran, Pietro Piazza, Hussam Dababneh, Riccardo Scarlatti, Calogero Catanzaro, Jacopo Pieri, Stefano Biolcati, Matteo Droghetti, Francesco Massari, Francesco Chessa, Lorenzo Bianchi, Riccardo Schiavina, Eugenio Brunocilla","doi":"10.23736/S2724-6051.25.06209-3","DOIUrl":"10.23736/S2724-6051.25.06209-3","url":null,"abstract":"<p><p>Robot-assisted nephroureterectomy (RANU) has demonstrated equal oncological outcomes and better perioperative outcomes compared to open and laparoscopic procedures for treating upper tract urothelial carcinoma (UTUC). However, RANU is still limited by technical difficulties like patient positioning, port placement, transitioning between anatomical regions and cost-effectiveness issues. The new surgical robot HUGO RAS increasing competition may spread the robotic approach also for this procedure. We aimed to demonstrate the feasibility of single docking RANU using HUGO RAS platform along with the description of our setting. We reported the first RANU performed in Europe at IRCCS Sant'Orsola Hospital (Bologna, Italy) using the HUGO^™ Robot-Assisted Surgery (RAS) System. Our main goal was to demonstrate the technical feasibility of RANU with HUGO^™ RAS along with its safety in terms of perioperative outcomes and complications. We also aimed to describe our surgical setup. We collected patient's characteristics, intraoperative and perioperative complications, docking time, operative time, clashing of the instruments, or technical errors of the system. The procedure was performed in a 78-year-old male with a clinically organ-confined high risk UTUC. No need for conversion to open/laparoscopic surgery was required. No intraoperative complications, instrument clashes or failure of the system that compromised the completion of the surgery were recorded. Docking, total operative, and console times were 7, 185 and 130 minutes, respectively. RANU with the HUGO^™ RAS System is a feasible and safe procedure in terms of perioperative outcomes and complications. Our setup allowed a rapid docking procedure and a smoothly completion of the surgery.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":"77 3","pages":"396-400"},"PeriodicalIF":4.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute kidney injury following retrograde intrarenal surgery (RIRS) with flexible and navigable suction ureteral access sheath (FANS): results from a prospective multicenter study.","authors":"Luigi Candela, Vineet Gauhar, Bhaskar Somani, Khi Y Fong, Satyndrea Persaud, Daniele Castellani, Nariman Gadzhiev, Vigen Malkhasyan, Chu A Chai, Boyke Soebhali, Mohammed Elshazly, Yiloren Tanidir, Karl M Tan, Saeed Bin Hamri, Steffi Yuen, Tzevat Tefik, Olivier Traxer","doi":"10.23736/S2724-6051.25.06274-3","DOIUrl":"10.23736/S2724-6051.25.06274-3","url":null,"abstract":"<p><strong>Background: </strong>Flexible and navigable suction ureteral access sheaths (FANS) have proven to be effective in reducing operative time and infectious complications and in increasing stone-free rate during retrograde intrarenal surgery (RIRS). FANS may reduce intrarenal pressure, thus reducing parenchymal renal damage. The aim of the present study was to assess acute kidney injury (AKI) rate following RIRS with FANS.</p><p><strong>Methods: </strong>This was a prospective multicenter study. Patients were enrolled between August 2023 and March 2024. Inclusion criteria were: patients aged ≥18 years with normal urinary anatomy who successfully underwent RIRS using FANS for renal stones. Complete baseline and perioperative data were collected. AKI was assessed at postoperative day 1 or 2 according to the KDIGO criteria. Intra and early postoperative complications, readmissions, and reinterventions up to 30 days post-surgery were documented. Univariable logistic regression (UVA) analysis was performed to identify predictors of AKI.</p><p><strong>Results: </strong>Two hundred an ten patients were eligible for analysis. The median stone volume was 1320 mm³. Median preoperative serum creatinine and eGFR were 0.94 mg/dL and 84 mL/min, respectively. The commonest FANS size used was 11-13 Ch (47%). A disposable scope was used in 55%, and TFL in 53% of surgeries. Median total laser time, ureteroscopy time, and operative times were 16.5, 31, and 49 minutes, respectively. At the end of the surgery, a double-J ureteral stent was placed in 84% of patients. AKI occurred in 13 (6.2%) patients. All cases were stage 1 AKI. At UVA, none of the preoperative or intraoperative variables were statistically associated with the occurrence of AKI (all P>0.05).</p><p><strong>Conclusions: </strong>AKI following RIRS with FANS is a not neglectable event and endourologist should be aware of this eventuality. However, all AKI episodes were mild. This study findings should be validated with a randomized controlled trial comparing outcomes of RIRS with and without FANS.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":"356-364"},"PeriodicalIF":4.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"YAU-RCC Spotlight: can we train immunity to cure RCC? Lessons from a neoantigen vaccine trial.","authors":"Veronica Mollica, Riccardo Campi, Daniele Amparore","doi":"10.23736/S2724-6051.25.06511-5","DOIUrl":"https://doi.org/10.23736/S2724-6051.25.06511-5","url":null,"abstract":"","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":"77 3","pages":"425-427"},"PeriodicalIF":4.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}